Automate Your Wheel Strategy on RMD
With Tiblio's Option Bot, you can configure your own wheel strategy including RMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RMD
- Rev/Share 36.8543
- Book/Share 43.1542
- PB 5.8259
- Debt/Equity 0.1341
- CurrentRatio 3.0597
- ROIC 0.1976
- MktCap 36697386980.0
- FreeCF/Share 12.2113
- PFCF 20.5172
- PE 24.7831
- Debt/Assets 0.0997
- DivYield 0.009
- ROE 0.2481
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RMD | Robert W. Baird | Outperform | Neutral | -- | $275 | Dec. 16, 2025 |
| Initiation | RMD | Citigroup | -- | Buy | -- | $330 | Sept. 18, 2025 |
| Upgrade | RMD | CLSA | Hold | Outperform | -- | -- | Sept. 2, 2025 |
| Upgrade | RMD | RBC Capital Mkts | Sector Perform | Outperform | -- | $294 | July 15, 2025 |
| Initiation | RMD | Morgan Stanley | -- | Overweight | -- | -- | March 19, 2025 |
| Initiation | RMD | Goldman | -- | Buy | -- | -- | Jan. 16, 2025 |
| Initiation | RMD | Piper Sandler | -- | Neutral | -- | $252 | Jan. 10, 2025 |
| Initiation | RMD | Stifel | -- | Hold | -- | $250 | Dec. 13, 2024 |
| Initiation | RMD | Robert W. Baird | -- | Outperform | -- | $280 | Sept. 24, 2024 |
| Downgrade | RMD | Wolfe Research | Peer Perform | Underperform | -- | $180 | Sept. 18, 2024 |
News
4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Read More
4 Medical Product Stocks to Watch From a Challenging Industry
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Negative
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Read More
Here's Why ResMed (RMD) is a Strong Momentum Stock
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Are Medical Stocks Lagging ResMed (RMD) This Year?
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Negative
Here is how ResMed (RMD) and Compass Therapeutics, Inc. (CMPX) have performed compared to their sector so far this year.
Read More
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Read More
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Neutral
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Bet on These 5 Low-Leverage Stocks to Avoid Industrial Volatilities
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Amid dwindling industry-specific volatilities, these five low-leverage stocks stand out as safer bets for investors seeking stability.
Read More
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Is This the Right Time to Add Resmed Stock to Your Portfolio?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Neutral
RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could weigh on future performance.
Read More
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Buy These 5 Low-Leverage Stocks Amid a Reversal of Santa Claus Rally
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
A stalled Santa Claus rally has investors rotating to stability, spotlighting low-leverage names like Resmed that may hold up better amid tech-led volatility.
Read More
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
Read More
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
Read More
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Should You Continue to Hold RMD Stock in Your Portfolio?
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.
Read More
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?
Published: November 24, 2025 by: Forbes
Sentiment: Neutral
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.
Read More
ResMed: Safe Bet For A Recession Environment
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive
ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and significant cash reserves position it favorably for investors who want to protect their portfolio for a recession. RMD's operational efficiency and cash balance support continued dividend growth and potential buybacks.
Read More
Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.
Read More
These Analysts Revise Their Forecasts On ResMed Following Q1 Results
Published: October 31, 2025 by: Benzinga
Sentiment: Positive
ResMed Inc. (NYSE:RMD) reported better-than-expected earnings for the first quarter on Thursday.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.
Read More
5 Low-Leverage Stocks to Buy as Market Takes a Tumble
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
As markets tumble, low-leverage stocks like RMD, SAFRY, PNR, CASY, and DRS offer safer investment options for steady returns.
Read More
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, RMD, VRT and NFG are some such stocks.
Read More
ResMed Inc. (RMD) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Neutral
ResMed Inc. (NYSE:RMD ) Bank of America Global Healthcare Conference 2025 September 23, 2025 8:20 AM EDT Company Participants Michael Farrell - CEO & Chairman Carlos Nunez - Chief Medical Officer Conference Call Participants Lyanne Harrison - BofA Securities, Research Division Presentation Lyanne Harrison BofA Securities, Research Division Good afternoon, everybody. My name is Lyanne Harrison.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Negative
RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
About ResMed Inc. (RMD)
- IPO Date 1995-06-02
- Website https://www.resmed.com
- Industry Medical - Instruments & Supplies
- CEO Michael J. Farrell
- Employees 9980